Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer (Q34754670)

4 August 2017

1 reference

title

Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer (English)

1 reference

4 August 2017

Julian Adams

1

1 reference

4 August 2017

1 August 2002

1 reference

Current Opinion in Chemical Biology

4 August 2017

1 reference

4 August 2017

6

1 reference

4 August 2017

4

1 reference

4 August 2017

493-500

1 reference

Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Structure of 20S proteasome from yeast at 2.4 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Catalytic mechanism of the 20S proteasome of Thermoplasma acidophilum revealed by X-ray crystallography

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Why does threonine, and not serine, function as the active site nucleophile in proteasomes?

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

How proteolysis drives the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Activation of the cell death program by inhibition of proteasome function

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I kappa B-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Activation of NF-kappa B requires proteolysis of the inhibitor I kappa B-alpha: signal-induced phosphorylation of I kappa B-alpha alone does not release active NF-kappa B

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L).

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

New insights into role of microenvironment in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

NF- kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF- kappa B

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Proteasome inhibition: a new strategy in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Development of the proteasome inhibitor PS-341.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

Proteasome inhibition in cancer: development of PS-341.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900343-5

7 January 2021

10.1016/S1367-5931(02)00343-5

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12133726